港股方面，今年以来吸引力回升，位列第三名，仅次于美股和欧洲市场，但绝对数值相差较大。1-7月 韩国资金净买入5.2亿美元，结束了2022-2024连续3年的资金净卖出。但6、7月整体呈现净卖出，流出 0.78亿美元。 东方财富首席策略官陈果分析表示，25年1-7月，韩国净买入美股140亿美元，欧洲市场74.5亿美元，港 股5.2亿美元，A股-0.5亿美元。6月中下旬港汇处于"弱方兑换保证"以来，港股对韩国投资者的吸引力边 际下降，韩国对港股的净买入转为卖出，6-7月累计净卖出7800万美元。 美股方面，韩国最大净流入权益资产，净买入占比高达99.79%。分月份看，5、6月美股净买入转负， 共净卖出15.4亿美元，7月净买入再次转正，净买入6.9亿美元。 科技板块受到追捧。1-7月，前5大净流入标的中，科技板块占据3个席位。其中，特斯拉及两倍看多位 居净买入前2位，共计净买入37.72亿美元，占对美股投资的31%。此外，区块链公司Circle Internet占据 净买入的第4名。 ETF吸引力高。1-7月，在前10大净流入标的中，有5个ETF；而在50大资金净流入标的中，ETF有19 个。这些ETF共计净买入 ...

截至2025年8月6日 10:32，中证香港创新药指数(931787)下跌1.33%。成分股方面涨跌互现，康希诺生物 (06185)领涨12.57%，晶泰控股(02228)上涨6.67%，远大医药(00512)上涨2.83%；君实生物(01877)领跌， 绿叶制药(02186)、三生制药(01530)跟跌。港股创新药ETF(513120)红盘蓄势。 流动性方面，港股创新药ETF盘中换手26.06%，成交43.40亿元，市场交投活跃。拉长时间看，截至8月 5日，港股创新药ETF近1周日均成交121.72亿元。 港股创新药ETF(513120)，（联接A:019670，联接C:019671）：紧密跟踪中证香港创新药指数，投资港 股创新药产业。值得注意的是，港股创新药ETF(513120)支持T+0交易，这意味着投资者可以在交易日 内进行多次买卖，极大地提高了资金的使用效率和流动性。 港股创新药ETF紧密跟踪中证香港创新药指数，根据申万二级行业分布，中证香港创新药指数生物制品 +化学制药权重占比达92.5%，这也是当下ETF跟踪的指数中，较为"纯血"的创新药行业指数之一。 数据显示，截至2025年7月31日，中证香 ...

Group 1 - The core viewpoint of the article highlights the recent stock performance of WuXi Biologics, which experienced a decline of 2.01% on August 6, trading at 31.22 HKD per share with a transaction volume of 4.38 billion HKD [1] - WuXi Biologics is recognized as a leading global provider of biologics services, offering comprehensive, integrated, and highly customized services throughout the entire process from discovery and development to production of biologics [1] - As of 2016, the company held a significant 48% market share in China's biologics R&D market and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Group 2 - For the fiscal year ending 2024, WuXi Biologics reported total revenue of 18.675 billion HKD and a net profit of 3.356 billion HKD [1] - The company is set to disclose its interim report for the fiscal year 2025 on August 19 [1]

Group 1 - The core viewpoint is that the Hong Kong innovative drug sector is experiencing significant growth, with the Hong Kong Innovative Drug Selected ETF seeing a rise of 1.2% and notable increases in individual stocks such as Jingtai Holdings and Lepu Biopharma [1] - The Hong Kong Innovative Drug Selected ETF (520690) has attracted substantial capital since its listing on August 1, with a net inflow of 29.54 million yuan over the past three trading days, bringing its total size to 359 million yuan [1] - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, focusing on leading innovative drug companies listed in Hong Kong, including companies like BeiGene, Innovent Biologics, WuXi Biologics, and others [1] Group 2 - The innovative drug sector is expected to remain a core focus within the pharmaceutical industry, with sustained optimism regarding its growth and internationalization [2] - The industry is anticipated to benefit from ongoing policy support, enhancing global competitiveness and commercial profitability [2] - The upcoming adjustments in medical insurance catalogs and the promotion of commercial insurance policies are seen as important catalysts for the innovative drug sector in the second half of the year [1]

Group 1 - The article provides a ranking of open-end funds based on their net asset value growth, highlighting the top 10 funds with significant increases [2][4][5] - The top-performing funds include Huatai-PB Hong Kong Stock Connect Medical Selected Mixed Fund A and C, with net values of 1.2442 and 1.2438 respectively, both showing a growth of 0.05 [2][4] - The article mentions that a total of 28,277 funds have updated their net values, indicating a broad market activity [3] Group 2 - The bottom 10 funds in terms of net value growth include Huafu Health and Entertainment Flexible Allocation Mixed Fund A and C, with significant declines [5] - The article notes that the Shanghai Composite Index experienced a rebound, while the ChiNext Index showed a mixed performance, with a trading volume of 1.61 trillion [7] - The leading sectors include communication equipment, which saw a rise of over 2%, while the aviation and software service sectors lagged [7] Group 3 - The article highlights that the top holdings in the funds are primarily in the pharmaceutical sector, with a concentration of 67.67% in the top 10 holdings of the funds [9] - Notable stocks among the top holdings include Innovent Biologics and WuXi Biologics, which experienced significant daily increases [9] - The funds are categorized into passive index funds tracking the Hong Kong Stock Connect Innovation Drug Index and active mixed funds focusing on the pharmaceutical sector [9]

Core Viewpoint - The China Securities Index for Hong Kong Stock Connect Medical Theme has shown significant growth, with a year-to-date increase of 58.75% [1] Group 1: Index Performance - The index rose by 2.58% to 1088.62 points, with a trading volume of 19.47 billion [1] - Over the past month, the index has increased by 16.48%, and over the last three months, it has risen by 31.51% [1] Group 2: Index Composition - The index comprises 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology [1] - The top ten weighted companies in the index include WuXi Biologics (15.03%), JD Health (10.75%), and WuXi AppTec (6.59%) [1] Group 3: Sector Allocation - The index's holdings are entirely from the Hong Kong Stock Exchange [2] - The sector breakdown of the index includes: Pharmaceuticals and Biotechnology Services (33.30%), Medical Services (32.85%), Medical Devices (12.81%), Chemical Drugs (12.34%), and Biological Drugs (8.70%) [2] Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special adjustments made under certain circumstances [2]

金融界8月5日消息，上证指数高开高走，中证港股通生物科技主题指数 (港股通生物科技，932253)报 1886.25点。 数据统计显示，中证港股通生物科技主题指数近一个月上涨22.20%，近三个月上涨54.39%，年至今上 涨108.66%。 据了解，中证港股通生物科技主题指数从港股通范围内选取50只业务涉及生物药品、制药与生物科技服 务等领域的上市公司证券作为指数样本，以反映港股通范围内生物科技主题上市公司证券的整体表现。 该指数以2018年12月28日为基日，以1000.0点为基点。 从指数持仓来看，中证港股通生物科技主题指数十大权重分别为：百济神州（13.23%）、信达生物 （12.79%）、药明生物（9.82%）、康方生物（8.87%）、中国生物制药（6.39%）、石药集团 （6.11%）、三生制药（4.69%）、翰森制药（3.27%）、药明康德（3.03%）、科伦博泰生物-B （2.67%）。 本文源自：金融界 作者：行情君 从中证港股通生物科技主题指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通生物科技主题指数持仓样本的行业来看，化学药占比40.03%、生物药品占比38.7 ...

金融界8月5日消息，上证指数高开高走，中证香港回购指数 (香港回购，932362)报1200.86点。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3、6、9、12月的第二个星期五的 下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个 定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指 数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。 数据统计显示，中证香港回购指数近一个月上涨8.48%，近三个月上涨21.50%，年至今上涨35.00%。 本文源自：金融界 据了解，中证香港回购指数从香港上市证券中选取50只回购比例较高的上市公司证券作为指数样本，以 反映香港证券市场高回购比例上市公司证券的整体表现。该指数以2018年12月28日为基日，以1000.0点 为基点。 作者：行情君 从指数持仓来看，中证香港回购指数十大权重分别为：快手-W（11.35%）、腾讯控股（9.76%）、友邦 保险（9.58%）、汇丰控股（9.45%）、中国建材（7.86%）、美团-W（7.62%）、太古股份公司Ａ ...

Core Viewpoint - The China Securities Hong Kong Stock Connect Repurchase Index has shown significant growth, with a 31.08% increase year-to-date, reflecting strong performance among companies with high repurchase ratios [1] Group 1: Index Performance - The China Securities Hong Kong Stock Connect Repurchase Index reported a 7.69% increase over the past month and a 19.83% increase over the past three months [1] - The index is based on 50 listed companies within the Hong Kong Stock Connect that have high repurchase ratios, with a base date of December 28, 2018, set at 1000.0 points [1] Group 2: Top Holdings - The top ten holdings of the index include Tencent Holdings (9.85%), Kuaishou-W (9.83%), AIA Group (9.67%), HSBC Holdings (9.53%), Meituan-W (7.69%), China National Building Material (6.65%), Swire Properties A (5.71%), COSCO Shipping Holdings (4.6%), China Hongqiao Group (4.4%), and WuXi Biologics (3.39%) [1] Group 3: Sector Allocation - The sector allocation of the index shows that finance accounts for 22.51%, communication services for 20.32%, industrials for 13.82%, consumer discretionary for 13.13%, materials for 11.55%, healthcare for 9.20%, real estate for 3.29%, energy for 2.61%, information technology for 2.53%, and consumer staples for 1.05% [2] Group 4: Index Adjustment Mechanism - The index samples are adjusted quarterly, with adjustments occurring on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]

市场分析人士指出，创新药行业已进入"真创新、真国际化"阶段，国内药企凭借工程师红利和临床资源 优势，正加速向全球市场拓展，未来现金流改善预期明确，行业长期成长逻辑坚实。相关标的涨幅居前 的背后，是创新药行业基本面的强劲支撑。今年以来，国内创新药出海动态频频，部分龙头药企达成超 百亿美元海外授权合作，推动行业估值快速修复。行业创新成果进入密集兑现期。 展望后市，中金公司（601995）表示，国内工程师红利、丰富临床资源和支持性政策多边加持下，未来 10年国产新药将深度参与全球市场，短期现金流入也将有效反哺研发形成良性循环，看好创新药长期产 业发展趋势。 中证网讯 8月5日，港股创新药ETF（513120）收涨3.17%，涨幅在全市场ETF中居首位。全天成交额突 破110亿元，位居全市场ETF前列。 数据显示，截至7月29日，该ETF今年以来收益超105%，最新规模已突破160亿元，不仅是全市场规模 最大的创新药ETF，也是今年业绩翻倍ETF中规模最大的基金。广发基金表示，规模、业绩的双重增长 充分展现出市场对创新药赛道的关注。 据介绍，港股创新药ETF（513120）跟踪中证香港创新药指数，聚焦创新药产业链，集 ...